[go: up one dir, main page]

WO2010018563A3 - Compositions and methods for the prognosis of lymphoma - Google Patents

Compositions and methods for the prognosis of lymphoma Download PDF

Info

Publication number
WO2010018563A3
WO2010018563A3 PCT/IL2009/000764 IL2009000764W WO2010018563A3 WO 2010018563 A3 WO2010018563 A3 WO 2010018563A3 IL 2009000764 W IL2009000764 W IL 2009000764W WO 2010018563 A3 WO2010018563 A3 WO 2010018563A3
Authority
WO
WIPO (PCT)
Prior art keywords
prognosis
compositions
lymphoma
methods
derived
Prior art date
Application number
PCT/IL2009/000764
Other languages
French (fr)
Other versions
WO2010018563A2 (en
Inventor
Moshe Hoshen
Gila Lithwick Yanai
Meir Lahav
Ranit Aharonov
Original Assignee
Rosetta Genomics Ltd.
Mor Research Applications Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosetta Genomics Ltd., Mor Research Applications Ltd. filed Critical Rosetta Genomics Ltd.
Publication of WO2010018563A2 publication Critical patent/WO2010018563A2/en
Publication of WO2010018563A3 publication Critical patent/WO2010018563A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Described herein are compositions and methods for prognosis of malignant lymphoma. The compositions are microRNA molecules associated with the prognosis of lymphoma, as well as various nucleic acid molecules relating thereto or derived thereof.
PCT/IL2009/000764 2008-08-12 2009-08-05 Compositions and methods for the prognosis of lymphoma WO2010018563A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8801508P 2008-08-12 2008-08-12
US61/088,015 2008-08-12

Publications (2)

Publication Number Publication Date
WO2010018563A2 WO2010018563A2 (en) 2010-02-18
WO2010018563A3 true WO2010018563A3 (en) 2010-04-15

Family

ID=41259376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2009/000764 WO2010018563A2 (en) 2008-08-12 2009-08-05 Compositions and methods for the prognosis of lymphoma

Country Status (1)

Country Link
WO (1) WO2010018563A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2922554T1 (en) 2012-11-26 2022-06-30 Modernatx, Inc. Terminally modified rna
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
CA2897941A1 (en) 2013-01-17 2014-07-24 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
WO2016077125A1 (en) 2014-11-10 2016-05-19 Moderna Therapeutics, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
US20210206818A1 (en) 2016-01-22 2021-07-08 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
SMT202300121T1 (en) 2016-05-18 2023-05-12 Modernatx Inc Polynucleotides encoding interleukin-12 (il12) and uses thereof
CA3027201A1 (en) 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
AU2017290614C1 (en) 2016-06-29 2024-01-18 Crispr Therapeutics Ag Materials and methods for treatment of friedreich ataxia and other related disorders
US11427838B2 (en) 2016-06-29 2022-08-30 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
WO2018002762A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
AU2017292169B2 (en) 2016-07-06 2021-12-23 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
US11459587B2 (en) 2016-07-06 2022-10-04 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
MX2019004810A (en) 2016-10-26 2019-10-15 Modernatx Inc Messenger ribonucleic acids for enhancing immune responses and methods of use thereof.
WO2018089540A1 (en) 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
BR112019015797A2 (en) 2017-02-01 2020-03-17 Modernatx, Inc. IMMUNOMODULATORY THERAPEUTIC MRNA COMPOSITIONS THAT CODE ACTIVATING ONCOGEN MUTATION PEPTIDES
EP3585900B1 (en) 2017-02-22 2022-12-21 CRISPR Therapeutics AG Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
US11407997B2 (en) 2017-02-22 2022-08-09 Crispr Therapeutics Ag Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
US11559588B2 (en) 2017-02-22 2023-01-24 Crispr Therapeutics Ag Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders
EP3585807A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
CA3054031A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Compositions and methods for gene editing
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
EP3675817A1 (en) 2017-08-31 2020-07-08 Modernatx, Inc. Methods of making lipid nanoparticles
US20190153440A1 (en) 2017-11-21 2019-05-23 Casebia Therapeutics Llp Materials and methods for treatment of autosomal dominant retinitis pigmentosa
JP7402163B2 (en) 2017-12-21 2023-12-20 クリスパー セラピューティクス アーゲー Materials and methods for the treatment of Usher syndrome type 2A
WO2019123430A1 (en) 2017-12-21 2019-06-27 Casebia Therapeutics Llp Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
CA3089117A1 (en) 2018-01-30 2019-08-08 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
WO2019200171A1 (en) 2018-04-11 2019-10-17 Modernatx, Inc. Messenger rna comprising functional rna elements
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN113271926A (en) 2018-09-20 2021-08-17 摩登纳特斯有限公司 Preparation of lipid nanoparticles and methods of administration thereof
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
BR112021014845A2 (en) 2019-01-31 2021-11-03 Modernatx Inc Lipid Nanoparticle Preparation Methods
US20230026259A1 (en) 2019-03-08 2023-01-26 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
MA56539A (en) 2019-06-24 2022-04-27 Modernatx Inc ENDONUCLEASE RESISTANT MESSENGER RNA AND USES THEREOF
US20220387628A1 (en) 2019-06-24 2022-12-08 Modernatx, Inc. Messenger rna comprising functional rna elements and uses thereof
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CN112941176A (en) * 2019-12-10 2021-06-11 复旦大学 Tumor lactic acid microenvironment related non-coding small RNA molecular spectrum and application thereof
IL294866A (en) 2020-01-31 2022-09-01 Modernatx Inc Methods for preparing fat nanoparticles
EP4185274A1 (en) 2020-07-24 2023-05-31 Strand Therapeutics Inc. Lipidnanoparticle comprising modified nucleotides
US20230277457A1 (en) 2020-08-06 2023-09-07 Modernatx, Inc. Methods of preparing lipid nanoparticles
MX2023008002A (en) 2021-01-08 2023-08-25 Expression constructs and uses thereof.
EP4334446A1 (en) 2021-05-03 2024-03-13 CureVac SE Improved nucleic acid sequence for cell type specific expression
EP4486890A1 (en) 2022-03-01 2025-01-08 CRISPR Therapeutics AG Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
US20250152737A1 (en) 2022-04-26 2025-05-15 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
EP4561547A1 (en) 2022-07-29 2025-06-04 ModernaTX, Inc. Lipid nanoparticle compositions comprising phospholipid derivatives and related uses
WO2024026475A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses
EP4561546A1 (en) 2022-07-29 2025-06-04 ModernaTX, Inc. Lipid nanoparticle compositions comprising surface lipid derivatives and related uses
WO2024259373A1 (en) 2023-06-14 2024-12-19 Modernatx, Inc. Compounds and compositions for delivery of therapeutic agents

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105360A1 (en) * 2004-02-09 2006-05-18 Croce Carlo M Diagnosis and treatment of cancers with microRNA located in or near cancer associated chromosomal features
EP1676914A1 (en) * 2003-09-22 2006-07-05 Aichi Prefecture Disease type of lymphoma and method of assessing prognosis
US20070072204A1 (en) * 2005-05-02 2007-03-29 Hannon Gregory J Compositions and methods for cancer diagnosis and treatment
WO2007148235A2 (en) * 2006-05-04 2007-12-27 Rosetta Genomics Ltd Cancer-related nucleic acids

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1676914A1 (en) * 2003-09-22 2006-07-05 Aichi Prefecture Disease type of lymphoma and method of assessing prognosis
US20060105360A1 (en) * 2004-02-09 2006-05-18 Croce Carlo M Diagnosis and treatment of cancers with microRNA located in or near cancer associated chromosomal features
US20070072204A1 (en) * 2005-05-02 2007-03-29 Hannon Gregory J Compositions and methods for cancer diagnosis and treatment
WO2007148235A2 (en) * 2006-05-04 2007-12-27 Rosetta Genomics Ltd Cancer-related nucleic acids

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, pages 841A, ISSN: 0006-4971 *
BLOOD, vol. 110, no. 11, Part 1, November 2007 (2007-11-01), 49TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 08 -11, 2007, pages 1049A, ISSN: 0006-4971 *
CALIN G A ET AL: "A MICRORNA SIGNATURE ASSOCIATED WITH PROGNOSIS AND PROGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 353, no. 17, 27 October 2005 (2005-10-27), pages 1793 - 1801, XP009058593, ISSN: 1533-4406 *
CALIN GEORGE A ET AL: "MicroRNA signatures in human cancers", NATURE REVIEWS. CANCER, NATUR PUBLISHING GROUP, LONDON, GB, vol. 6, no. 11, 1 November 2006 (2006-11-01), pages 857 - 866, XP002473506, ISSN: 1474-175X *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2005 (2005-11-01), LAWRIE CHARLES H ET AL: "MicroRNA expression profiling of diffuse large B-cell lymphoma reveals differences between germinal center-like and activated B cell-like subtypes.", XP002554909, Database accession no. PREV200600185370 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2007 (2007-11-01), ROBERTUS JAN-LUKAS ET AL: "Differences in the C13orf25 miRNA cluster in non-Hodgkin lymphoma and normal B-Cell subtypes", XP002554910, Database accession no. PREV200800218858 *
EIS P S ET AL: "Accumulation of miR-155 and BIC RNA in human B cell lymphomas", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 102, no. 10, 1 March 2005 (2005-03-01), pages 3627 - 3632, XP002396794, ISSN: 0027-8424 *
HE LIN ET AL: "A microRNA polycistron as a potential human oncogene", NATURE (LONDON), vol. 435, no. 7043, June 2005 (2005-06-01), pages 828 - 833, XP002554907, ISSN: 0028-0836 *
LAWRIE CHARLES H ET AL: "Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma", BRITISH JOURNAL OF HAEMATOLOGY,, vol. 141, no. 5, 3 March 2008 (2008-03-03), pages 672 - 675, XP002545705 *
LAWRIE CHARLES H ET AL: "MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma", INTERNATIONAL JOURNAL OF CANCER, vol. 121, no. 5, September 2007 (2007-09-01), pages 1156 - 1161, XP002554905, ISSN: 0020-7136 *
OTA A ET AL: "Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 64, no. 9, 1 May 2004 (2004-05-01), pages 3087 - 3095, XP002996247, ISSN: 0008-5472 *
ROEHLE ANJA ET AL: "MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas.", BRITISH JOURNAL OF HAEMATOLOGY SEP 2008, vol. 142, no. 5, 5 June 2008 (2008-06-05), pages 732 - 744, XP002554906, ISSN: 1365-2141 *
TAGAWA HIROYUKI ET AL: "Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development", CANCER SCIENCE, vol. 98, no. 9, September 2007 (2007-09-01), pages 1482 - 1490, XP002554908, ISSN: 1347-9032 *
TANZER A ET AL: "Molecular Evolution of a MicroRNA Cluster", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 339, no. 2, 28 May 2004 (2004-05-28), pages 327 - 335, XP004506520, ISSN: 0022-2836 *

Also Published As

Publication number Publication date
WO2010018563A2 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
WO2010018563A3 (en) Compositions and methods for the prognosis of lymphoma
WO2009108866A3 (en) Microrna signatures associated with cytogenetics and prognosis in acute myeloid leukemia (aml) and uses thereof
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
WO2010099161A8 (en) Micrornas in never-smokers and related materials and methods
WO2009108860A3 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2009061381A3 (en) Alpha-amylase variants with altered properties
WO2009108217A3 (en) Compositions comprising k-ras sirna and methods of use
WO2009153775A3 (en) Methods for distinguishing between specific types of lung cancers
WO2007148235A3 (en) Cancer-related nucleic acids
WO2010127304A3 (en) Sequencing methods
WO2010048585A3 (en) Oligomeric compounds and methods
WO2008069906A3 (en) Digital expression of gene analysis
WO2009012263A3 (en) Tissue-specific micrornas and compositions and uses thereof
WO2014028429A3 (en) Enzymes and polymerases for the synthesis of rna
WO2009039189A3 (en) Compositions comprising stat3 sirna and methods of use thereof
WO2011156654A3 (en) Pathways characterization of cells
WO2009108918A3 (en) Methods and systems for social networking based on nucleic acid sequences
WO2008152131A3 (en) Rnai inhibition of alpha-enac expression
WO2010045384A3 (en) Short hairpin rnas for inhibition of gene expression
WO2009153774A3 (en) Compositions and methods for prognosis of ovarian cancer
WO2007014077A3 (en) Rnai modulation of the rho-a gene and uses thereof
WO2011160052A3 (en) Methods and compositions for sequence specific rna endonucleases
WO2009120712A3 (en) Compositions and methods for diagnosing and treating melanoma
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09787509

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09787509

Country of ref document: EP

Kind code of ref document: A2